2 photos

• Sort by: number of views (most to least) number of views (least to most) number of comments (most to least) number of comments (least to most) number of favorites (most to least) number of favorites (least to most) date uploaded (newest first) date uploaded (oldest first) random

• Figure 5: Decrease in FDA First Cycle Review Time for Abbreviated New Drug Applications, Fiscal Years 2013 through 2015

  • Uploaded by: U.S. Government Accountability Office
  • License: United States Government Work
  • 0 comments
  • 0 favorites
  • 3,303 views
  • Date uploaded: 2017-06-27
  • Tags: gao, governmentaccountabilityoffice, usgovernmentaccountabilityoffice, usgao, unitedstatesgovernmentaccountabilityoffice, government, congress, watchdog, oversight, governmentwatchdog, gao17452, genericdruguserfees, anda, abbreviatednewdrugapplication, cber, centerforbiologicsevaluationandresearch, cder, centerfordrugevaluationandresearch, fda, foodanddrugadministration, fy, fiscalyear, gdufa, genericdruguserfeeamendmentsof2012, hhs, departmentofhealthandhumanservices, hq, headquarters, it, informationtechnology, ogd, officeofgenericdrugs, ora, officeofregulatoryaffairs, pas, priorapprovalsupplement
  • Visibility: public
• Figure 6: Decrease in FDA First Cycle Review Time for Prior Approval Supplements, Fiscal Years 2013 through 2015

  • Uploaded by: U.S. Government Accountability Office
  • License: United States Government Work
  • 0 comments
  • 0 favorites
  • 3,197 views
  • Date uploaded: 2017-06-27
  • Tags: gao, governmentaccountabilityoffice, usgovernmentaccountabilityoffice, usgao, unitedstatesgovernmentaccountabilityoffice, government, congress, watchdog, oversight, governmentwatchdog, gao17452, genericdruguserfees, anda, abbreviatednewdrugapplication, cber, centerforbiologicsevaluationandresearch, cder, centerfordrugevaluationandresearch, fda, foodanddrugadministration, fy, fiscalyear, gdufa, genericdruguserfeeamendmentsof2012, hhs, departmentofhealthandhumanservices, hq, headquarters, it, informationtechnology, ogd, officeofgenericdrugs, ora, officeofregulatoryaffairs, pas, priorapprovalsupplement
  • Visibility: public